Apr. 7 at 3:06 PM
$CRVO Our commitment to the DLB community is central to all that we do at CervoMed. That’s why days like today, when members of our leadership team will have the opportunity to engage with patient advocates, physicians and people with DLB and their families at the Lewy Body Dementia Association Annual Meeting, are so important to us.
At the meeting, we’ll be sharing updates on our neflamapimod program, including:
*New MRI analyses from the Phase 2b RewinD-LB clinical trial
*Status of global regulatory discussions
*Finalized Phase 3 trial design
The data from the MRI analyses will also be featured at 2026 American Academy of Neurology Annual Meeting later this month.
You can read more here: https://lnkd.in/egucATFP
#PatientAdvocacy #neflamapimod #DLB
